DIFFICULTY CHEWING
He avoids having meals with family and friends.
Adult patients with anti-AChR antibody-positive generalized myasthenia gravis (gMG) may not always experience adequate symptom control. Listen to the following 5 stories and learn how these adult patients could be right for SOLIRIS.
Learn more about this patient and his journey with anti-AChR antibody-positive gMG, including some of the symptoms he experiences:
He avoids having meals with family and friends.
He schedules his meetings in the morning because his speech becomes slurred in the afternoon.
Watch the video to find out if he could be right for SOLIRIS.
Learn more about this patient and her journey with anti-AChR antibody-positive gMG, including some of the symptoms she experiences:
She requires frequent rest throughout the day, which cuts into the amount of time she spends with her family.
She jam-packs her mornings with daily activities before her fatigue sets in.
Watch the video to find out if she could be right for SOLIRIS.
Learn more about this patient and his journey with anti-AChR antibody-positive gMG, including some of the symptoms he experiences:
He doesn’t make plans with friends or family because they may not understand him.
He eats lunch alone at work because he’s embarrassed for people to see him.
Watch the video to find out if he could be right for SOLIRIS.
Learn more about this patient and her journey with anti-AChR antibody-positive gMG, including some of the symptoms she experiences:
She requires frequent rest throughout the day, which reduces the time she spends with family.
She doesn’t have the strength to comb her hair or dress herself.
Watch the video to find out if she could be right for SOLIRIS.
Learn more about this patient and her journey with anti-AChR antibody-positive gMG, including some of the symptoms she experiences:
She is constantly thinking about when she’ll have to rest during the day.
She avoids talking to people because they may not be able to understand her.
Watch the video to find out if she could be right for SOLIRIS.
Particularly those who present with:
restricting use of conventional therapies
from immunosuppressive or symptomatic therapy
Learn about safety in REGAIN and the Open-label Extension Study.
See the dataThe use of Soliris increases a patient’s susceptibility to serious meningococcal infections (septicemia and/or meningitis).
Vaccinate or revaccinate for meningococcal disease according to the most current ACIP recommendations for patients with complement deficiencies. Immunize patients without a history of meningococcal vaccination at least 2 weeks prior to receiving the first dose of Soliris. If Soliris must be initiated immediately in an unvaccinated patient, administer meningococcal vaccine(s) as soon as possible and provide 2 weeks of antibacterial drug prophylaxis. Discontinue Soliris in patients who are undergoing treatment for serious meningococcal infections.
Prescribers must counsel patients about the risk of meningococcal infection, provide the patients with the REMS educational materials, and ensure patients are vaccinated with meningococcal vaccine(s).
Serious infections with Neisseria species (other than N. meningitidis), including disseminated gonococcal infections, have been reported.
Patients may have increased susceptibility to infections, especially with encapsulated bacteria. Additionally, Aspergillus infections have occurred in immunocompromised and neutropenic patients. Use caution when administering Soliris to patients with any systemic infection.
Administration of Soliris may result in infusion-related reactions, including anaphylaxis or other hypersensitivity reactions. Interrupt Soliris infusion and institute appropriate supportive measures if signs of cardiovascular instability or respiratory compromise occur.
The most frequently reported adverse reaction in the gMG placebo-controlled clinical trial (≥10%) is: musculoskeletal pain.
Soliris is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
Please see full Prescribing Information for SOLIRIS, including Boxed WARNING regarding serious meningococcal infections.
The use of Soliris increases a patient’s susceptibility to serious meningococcal infections (septicemia and/or meningitis).
Vaccinate or revaccinate for meningococcal disease according to the most current ACIP recommendations for patients with complement deficiencies. Immunize patients without a history of meningococcal vaccination at least 2 weeks prior to receiving the first dose of Soliris. If Soliris must be initiated immediately in an unvaccinated patient, administer meningococcal vaccine(s) as soon as possible and provide 2 weeks of antibacterial drug prophylaxis. Discontinue Soliris in patients who are undergoing treatment for serious meningococcal infections.
Prescribers must counsel patients about the risk of meningococcal infection, provide the patients with the REMS educational materials, and ensure patients are vaccinated with meningococcal vaccine(s).
Serious infections with Neisseria species (other than N. meningitidis), including disseminated gonococcal infections, have been reported.
Patients may have increased susceptibility to infections, especially with encapsulated bacteria. Additionally, Aspergillus infections have occurred in immunocompromised and neutropenic patients. Use caution when administering Soliris to patients with any systemic infection.
Administration of Soliris may result in infusion-related reactions, including anaphylaxis or other hypersensitivity reactions. Interrupt Soliris infusion and institute appropriate supportive measures if signs of cardiovascular instability or respiratory compromise occur.
The most frequently reported adverse reaction in the gMG placebo-controlled clinical trial (≥10%) is: musculoskeletal pain.
Soliris is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
Please see full Prescribing Information for SOLIRIS, including Boxed WARNING regarding serious meningococcal infections.
References: